NASDAQFinancialsFinancial - ConglomeratesSnapshot 2026-11-04
The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.
Next-FY EPS estimate change · 30 days
Matching fiscal periods, usable estimates and at least one analyst are required.
One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.
The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.
The EPS and P/E reference is not available for RILY yet.
| Measure / period | Management expectations | Analyst expectations |
|---|
Management figures unavailable.
Current consensus figures unavailable.
Three published thesis conditions, with dated milestones shown separately.
| Key Factor | Why It Matters | Current Status | Break Condition | Latest Evidence |
|---|---|---|---|---|
EPS to reach at least $6.57 in Q1 2026 | A primary condition in BRC, Inc.'s published investment case. The stated target is >= $6.57 per share. | Broken | EPS falls below $6.57 in 2026-Q1 | Diluted EPS: $0.45 per share FY2026-Q2; GAAP. Published target: >= $6.57 per share. The stored target says 2026-Q1; this source reports FY2026-Q2. Fiscal/calendar alignment needs review. Aug 6, 20260.45 USD/share · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Compare these dated observations with the operating requirements above
Comparable estimate history is unavailable.
Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.
Compare required revenue and earningsMonthly analyst history is unavailable.
Recent actions · Oct 6–Nov 4 · 0 recorded
The evidence, the remaining questions, and what comes next
No recovery evidence is reported in the available driver assessments.
Nov 5, 2026
Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.
Observed price history; separate from operating scenarios
The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.
This is a high-risk financial company with a recovery element, rather than a steady compounder. Its thesis state is weakened: recent performance has slipped relative to its industry, even as the overall signal improved.
The valuation is described as cheap versus peers, while the model suggests expectations are somewhat ahead of the fundamentals. Pricing fragility is low, but that does not remove the gap between expectations and execution.
Near term, revenue and adjusted operating profitability have improved, and net debt has fallen. However, the company recently missed its own guidance, the risk of another earnings miss is elevated, and debt reduction is behind management’s stated priority.
The multi-year thesis depends on sustained revenue and profit improvement alongside further balance-sheet strengthening. Near term, a guidance cut or falling rates would be unfavorable, while continued strength among major financial firms could support the sector backdrop; recent acquisition activity and litigation add uncertainty.
Over the next 1 to 3 years, RILY’s improving operating results are balanced by volatile management execution, elevated near-term risk, and a weakened thesis state. Not investment advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| Operating income rose from $10.8M to $153M. |
| Under Pressure |
| Operating income falls below $150 million in next 4 quarters |
Operating income: $38.195M FY2026-Q2; GAAP. Published target: >= $150 million. Target period is not explicitly aligned with this observation. Aug 6, 202638,195,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Revenue growth to at least $967.6M in 2025 | A primary condition in BRC, Inc.'s published investment case. The stated target is >= $967.6 million. | Intact | Revenue falls below $967.6 million in FY25 | Revenue: $239.117M FY2026-Q2; GAAP. Published target: >= $967.6 million. Annual target cannot be compared with a quarterly or TTM observation. Aug 6, 2026239,117,000 USD · source valueLast status assessment Nov 4, 2026Compare required operating outcomesCompare scope, accounting basis and period before treating this evidence as progress against an annual requirement. |
Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.
Individual price-target observations are unavailable.
0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior
Oct 6, 2026–Nov 4, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.
3 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.
The dated weekly assessment and its assumptions are available in Read detailed Outlook.